April 8, 2019
PledPharma AB today announces that the Annual Report for 2018 now is available at the company’s website, www.pledpharma.se. A printed version can be ordered through [email protected] or +468 -679 72 10.
For further information, please contact:
Yilmaz Mahshid, CFO
Tel. +46-(0)72 231 68 00
About Us
PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company’s most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A global phase III program is ongoing. The drug candidate Aladote® is being developed to reduce the risk of acute liver injury associated with acetaminophen poisoning. A proof of principle study has been successfully completed and will serve as the basis for the continued development. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 83 00, [email protected]). For more information, see http://www.pledpharma.com/
